ALUMIS INC. (ALMS) FY2024 10-K Annual Report
ALUMIS INC. (ALMS) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 19, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ALUMIS INC. FY2024 10-K Analysis
Business Overview
- • Core business: Clinical-stage biopharmaceutical developing precision TYK2 inhibition therapies for immune-mediated diseases
- • New emphasis: Initiated Phase 1 trial of CNS-penetrant TYK2 inhibitor A-005 targeting MS and neurodegenerative diseases, reporting initial results in Dec 2024
Management Discussion & Analysis
- • Revenue, profit, segment, cash flow, and guidance data not disclosed in provided text
Risk Factors
- • Regulatory risk: FDA current cGMP compliance reliance on CMOs for manufacturing, with no own facilities impacting supply chain control
- • Macroeconomic threat: ongoing Ukraine and Israel conflicts potentially disrupting operations and financing access amid global instability
ALUMIS INC. FY2024 Key Financial MetricsXBRL
Net Income
-$294M
▼ -89.8% YoY
ROE
-113.1%
▼ -15881bp YoY
Total Assets
$341M
▲ +280.5% YoY
EPS (Diluted)
$-10.38
▲ +85.6% YoY
Operating Cash Flow
-$255M
▼ -96.3% YoY
Source: XBRL data from ALUMIS INC. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ALUMIS INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.